Read by QxMD icon Read

Journal of Medical Economics

Maria Isabel Toulson Davisson Correia, Mario Ignacio Perman, Lorenzo Pradelli, AbdulJabbar Omaralsaleh, Dan Linetzky Waitzberg
AIM: Disease related malnutrition (DRM) is a prevalent condition that significantly increases the risk of adverse outcomes in hospitalized patients, particularly those with critical illness. Limited data are available on the economic burden of DRM and the potential cost-benefit of nutrition therapy in high-risk populations in Latin America. The aims of the present study were to estimate the economic burden of DRM and evaluate the cost-benefit of supplemental parenteral nutrition (SPN) in critically ill patients who fail to receive adequate nutrient intake from enteral nutrition (EN) in Latin America...
July 13, 2018: Journal of Medical Economics
Ahong Huang, Tony B Amos, Kruti Joshi, Li Wang, Abigail Nash
BACKGROUND: Schizophrenia is a serious public health problem that affects ∼1% of the US population. AIMS: To examine treatment patterns and evaluate healthcare resource utilization and costs among young adults (18-35 years) with schizophrenia who were early in the disease. MATERIALS AND METHODS: Patients aged 18-64 years with ≥2 schizophrenia diagnoses in the identification period (01JAN2012-30SEPT2015) and continuous enrollment for ≥12 months pre- and post-index date were identified from the OptumInsight Clinformatics DataMart...
July 13, 2018: Journal of Medical Economics
Keith D Mortman, Mitra Corral, Xiaohong Zhang, Indrias Berhane, Ireena M Soleas, Nicole C Ferko
AIM: Progel™ Pleural Air Leak Sealant (Progel™) is currently the only sealant approved by the FDA for the treatment of air leaks during lung surgery. This study was performed to determine whether Progel™ use improves hospital length of stay (LOS) and hospitalization costs compared with other synthetic/fibrin sealants in patients undergoing lung surgery. METHODS: The U.S. Premier hospital database was used to identify lung surgery discharges from January 1, 2010 to June 30, 2015...
July 12, 2018: Journal of Medical Economics
Panagiotis Petrou
No abstract text is available yet for this article.
July 11, 2018: Journal of Medical Economics
E Nasonov, S Soloviev, J E Davidson, A Lila, G Togizbayev, R Ivanova, Ch Baimukhamedov, Zh Omarbekova, O Iaremenko, A Gnylorybov, S Shevchuk, A Vasylyev, J Makarova, L Tariq
OBJECTIVES: To evaluate healthcare resource (HR) consumption associated with Systemic Lupus Erythematosus (SLE) management in adult patients with active autoantibody positive disease in the Russian Federation, Republic of Kazakhstan and Ukraine. METHODS: The ESSENCE was a retrospective, observational study, and included data on patients' clinical characteristics and SLE-related HR use (laboratory, biopsy, imaging tests, medications, visits to specialists, outpatient visits, hospitalisations) during 2010 from the 12 specialised rheumatologic centres...
July 11, 2018: Journal of Medical Economics
Crystal Man Ying Lee, Brandon Goode, Emil Nørtoft, Jonathan E Shaw, Dianna J Magliano, Stephen Colagiuri
AIMS: To assess and compare the direct healthcare and non-healthcare costs and government subsidies by body weight and diabetes status. METHODS: The Australian Diabetes, Obesity and Lifestyle study collected health service utilisation and health related expenditure data at the 2011-12 follow-up surveys. Costing data were available on 4409 participants. Unit costs for 2016-17 were used where available or were otherwise inflated to 2016-17 dollars. Age- and sex-adjusted costs per person were estimated using generalised linear models...
July 6, 2018: Journal of Medical Economics
Márcio Augusto Averbeck, Andrei Krassioukov, Nikesh Thiruchelvam, Helmut Madersbacher, Mette Bøgelund, Yasuhiko Igawa
AIMS: Intermittent catheterization (IC) is the gold standard for bladder management in patients with chronic urinary retention. Despite its medical benefits, IC users experience a negative impact on their quality of life (QoL). For health economics based decision making, this impact is normally measured using generic QoL measures (such as EQ-5D) that estimate a single utility score which can be used to calculate quality-adjusted life years (QALYs). But these generic measures may not be sensitive to all relevant aspects of QoL affected by intermittent catheters...
July 6, 2018: Journal of Medical Economics
Adam Cohen, Julia A Gaebler, Jessica Izhakoff, Laura Gullett, Timothy Niecko, Thomas O'Donnell
AIMS: To assess the budget impact to a US commercial health plan of providing access to the Flexitouch (FLX) advanced pneumatic compression device (Tactile Medical) to lymphedema (LE) patients with either comorbid chronic venous insufficiency (CVI) or frequent infections. METHODS: Budget impact was calculated over 2 years for a hypothetical US payer with 10-million commercial members. Model inputs were derived from published sources and from a case-matched analysis of Blue Health Intelligence (BHI) claims data for the years 2012-2016...
July 5, 2018: Journal of Medical Economics
Wenqing Su, Fang Chen, Timothy M Dall, Tracy Zvenyach, Theodore K Kyle, Leigh Perreault
INTRODUCTION: There is a critical need to focus limited resources on subgroups of patients with obesity where we expect the largest return on investment. This paper identifies patient subgroups where an investment may result in larger positive economic and health outcomes. METHODS: The baseline population with obesity was derived from a public survey database and divided into subpopulations defined by demographics and disease status. In 2016 we used a validated model to simulate the incidence of diabetes, absenteeism, and direct medical cost in five care settings...
July 5, 2018: Journal of Medical Economics
Kathleen Mary Noon, Stephen Maxwell Montgomery, Nicholas Edward Adlard, Michel Anton Kroes
OBJECTIVES: Specific economic model types often become de facto standard for health technology appraisal over time. Markov and discrete event simulation (DES) models were compared to investigate the impact of innovative modeling on the cost-effectiveness of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS). Fingolimod was compared to dimethyl fumarate (DMF; in highly active [HA] RRMS), alemtuzumab (in HA RRMS) and natalizumab (in rapidly evolving severe RRMS)...
July 5, 2018: Journal of Medical Economics
Shweta Shah, Christopher M Blanchette, Joseph C Coyle, Marc Kowalkowski, Susan T Arthur, Reuben Howden
AIM: To estimate the healthcare utilization and costs in elderly lung cancer patients with and without pre-existing chronic obstructive pulmonary disease (COPD). METHODS: Using Surveillance, Epidemiology and End Results (SEER)-Medicare data, this study identified patients with lung cancer between 2006-2010, at least 66 years of age, and continuously enrolled in Medicare Parts A and B in the 12 months prior to cancer diagnosis. The diagnosis of pre-existing COPD in lung cancer patients was identified using ICD-9 codes...
July 2, 2018: Journal of Medical Economics
Matteo Ruggeri, Michele Basile, Andrea Zini, Salvatore Mangiafico, Elio Clemente Agostoni, Kyriakos Lobotesis, Jeffrey Saver, Silvia Coretti, Cralo Drago, Americo Cicchetti
BACKGROUND: Stroke has a significant disease burden in terms of acute and long-term disability in Italy and throughout the world. Endovascular treatments for the management of a stroke event have been coupled in the past years with the possibility to mechanically remove the occlusion by means of specially designed thrombectomy devices, and their exclusive use showed levels of effectiveness in line with those of the existing pharmacological treatments. OBJECTIVE: To assess the cost-effectiveness of mechanical thrombectomy (MT) with the Solitaire Revascularization Device (stent retriever) for the treatment of acute ischemic stroke (AIS) in patients with large vessel occlusions (LVOs), comparing MT plus intravenous tissue plasminogen activation (MT plus IV t-PA) vs IV t-PA alone, in Italy...
June 28, 2018: Journal of Medical Economics
Matthew Hirst, Matthew W Bending, Gianluca Baio, Amina Yesufu-Udechuku, William C N Dunlop
AIMS: The study objective was to develop an open-source replicate of a cost-effectiveness model developed by National Institute for Health and Care (NICE), in order to explore uncertainties in health economic modeling of novel pharmacological neuropathic pain treatments. MATERIALS AND METHODS: The NICE model, consisting of a decision tree with branches for discrete levels of pain relief and adverse event (AE) severities, was replicated using R, and used to compare a hypothetical neuropathic pain drug to pregabalin...
June 25, 2018: Journal of Medical Economics
(no author information available yet)
No abstract text is available yet for this article.
June 22, 2018: Journal of Medical Economics
Zsolt Hepp, Maureen J Lage, Ramon Espaillat, Ved V Gossain
OBJECTIVE: To evaluate outcomes associated with adherence to levothyroxine (LT4) in the US adult hypothyroidism population. METHODS: We used data from Truven's MarketScan databases from 1 July 2011 through 31 December 2015. Patients aged 18 or older were diagnosed with hypothyroidism (confirmed at least twice) and prescribed LT4. Patients were excluded if they did not have continuous insurance coverage or if they received a diagnosis of thyroid cancer or pregnancy during the study period...
June 22, 2018: Journal of Medical Economics
Alexandre Gherardi, Stéphane Roze, Johan Kuijvenhoven, Ola Ghatnekar, Yum Lina Yip Sonderegger
AIMS: Budesonide with multi-matrix technology (MMX) is an oral corticosteroid, shown to have high topical activity against ulcerative colitis (UC) while maintaining low systemic bioavailability with few adverse events. The aim of this study was to evaluate the cost-effectiveness of budesonide MMX versus commonly used corticosteroids, in the second-line treatment of active mild-to-moderate UC in the Netherlands. MATERIALS AND METHODS: An eight-state Markov model with an 8 week cycle length captured remission, four distinct therapy stages, hospitalization, possible colectomy and mortality...
June 22, 2018: Journal of Medical Economics
Omondi Michelle Atieno, Sylvia Opanga, Antony Martin, Amanj Kurdi, Brian Godman
BACKGROUND: Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable burden on households if family members develop cancer. However, the actual cost of cancer treatment in Kenya is unknown. Such an analysis is essential to better allocate resources as Kenya strives towards universal healthcare...
June 21, 2018: Journal of Medical Economics
Arpamas Seetasith, Mallik Greene, Ann Hartry, Chakkarin Burudpakdee
AIMS: The study compared all-cause and major depressive disorder (MDD)-related healthcare resource use (HRU) and costs in patients with MDD treated with atypical antipsychotic (AAP) adjunctive therapy early or later in treatment. MATERIALS AND METHODS: Adults with MDD and antidepressant treatment (ADT) who newly initiated adjunctive aripiprazole, brexpiprazole, lurasidone, or quetiapine between October 1, 2014 and September 30, 2015 were identified in the IQVIA Real-World Data Adjudicated Claims database; the index date was the date of the first AAP claim...
June 19, 2018: Journal of Medical Economics
Christine L Barnett, Deirdre Mladsi, Michael Vredenburg, Kavita Aggarwal
AIMS: This study aimed to estimate the cost of platelet transfusion in patients with chronic liver disease (CLD)-associated thrombocytopenia undergoing an elective procedure in the United States. MATERIALS AND METHODS: The study was conducted in 2 parts: development of a conceptual framework identifying direct, indirect, and intangible costs of platelet transfusion, followed by the estimation of the total cost of platelet transfusion in patients with CLD-associated thrombocytopenia before an elective procedure in the United States using the conceptual framework and cost data obtained from a literature search...
June 18, 2018: Journal of Medical Economics
M A Piena, M Heisen, L W Wormhoudt, J van Wingerden, S T F M Frequin, B M J Uitdehaag
AIM: In active relapsing remitting multiple sclerosis (RRMS) patients requiring second-line treatment, the Dutch National Health Care Institute (ZiN) has not stated a preference for either alemtuzumab, fingolimod or natalizumab. Our aim was to give healthcare decision-makers insight into the differences in cost accumulation over time between alemtuzumab - with a unique, non-continuous treatment schedule - and fingolimod and natalizumab for second-line treatment of active RRMS patients in the Netherlands...
June 18, 2018: Journal of Medical Economics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"